Based on the available information, there is no explicit statement regarding the administration of Cosentyx after receiving live vaccines. However, the National Center for Biotechnology Information (NCBI) article [2] mentions that Cosentyx (secukinumab) is a human monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the inflammatory response of several diseases.

The Centers for Disease Control and Prevention (CDC) [3] states that live vaccines generally contain a weakened form of the virus they are designed to protect against. As a result, individuals with weakened immune systems due to medications or conditions should avoid live vaccines because their bodies may not be able to handle the weakened virus, and the vaccine may cause the disease it is supposed to prevent.

While the article [2] does not mention any interaction between Cosentyx and live vaccines, it does state that "the safety and efficacy of secukinumab in patients with a history of chronic or recurrent infections have not been established." Therefore, it is essential to consult with a healthcare provider before administering any live vaccine to a patient taking Cosentyx.

In summary, while there is no explicit statement regarding the administration of Cosentyx after receiving live vaccines, it is crucial to consult with a healthcare provider before administering any live vaccine to a patient taking Cosentyx due to the potential risks associated with live vaccines and the patient's weakened immune system.

Sources:

* [Cosentyx DrugPatentWatch](https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX)
* [Secukinumab for the treatment of psoriasis: a systematic review and network meta-analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235258/)
* [Immunocompromised Travelers](https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-considerations/immunocompromised-travelers)